BIO-Europe 2022
October 24-26, Leipzig
News
- Aplagon Signed EIC-Accelerator Grant Agreement 16 November 2022 - HELSINKI, November 16, 2022. Aplagon Oy (Aplagon), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic agents (APACs) to treat vascular injury related blood vessel occlusions and tissue damage, today announced that it had signed an EIC Accelerator grant agreement (Grant Agreement) with the European Innovation Council and SMEs Executive… read more »
- Aplagon Joins The TRACER Excellence Program to Perform In-Human Imaging Study 8 September 2022 - HELSINKI, FINLAND and GRONINGEN, THE NETHERLANDS, September 8, 2022. Today, Aplagon Oy (“Aplagon”) announced that it will start its in-human imaging study to visualize the effect of its innovative APAC compound in patients with peripheral arterial occlusive disease / critical limb ischemia. The study will be executed in collaboration with… read more »
- First Patient Treated in First Clinical Study for Aplagon’s APAC 7 June 2022 - HELSINKI, June 7, 2022. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic agents to treat vascular injury related blood vessel occlusions and tissue damage, today announced that its lead pharmaceutical agent, APAC, has been administered for the first time in a clinical study. The Phase 1… read more »
- Aplagon Publishes New Data in Prestigious Journal of Cardiovascular Pharmacology 1 September 2021 - HELSINKI, September 1, 2021. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic compounds to treat vascular injury related blood vessel occlusions and tissue damage, today announced the publication of new data as well as an accompanying commentary by third-party experts in the leading, peer-reviewed Journal of… read more »
- Aplagon Closes Oversubscribed EUR 2.2M Funding Round 28 May 2021 - HELSINKI, May 28, 2021. Aplagon Oy (“Aplagon”), the Finnish pharmaceutical development company developing first-in-class vasculoprotective antithrombotic compounds to treat vascular injury related blood vessel occlusions and tissue damage, today announced the closing of a EUR 2.2 million funding round. The fundraise was arranged in collaboration with Invesdor Group and was… read more »
- Aplagon Partners with Cadila Pharmaceuticals to Develop and Commercialize APAC First-in-Class Antithrombotics for the Prevention of Blood Vessel Occlusions Related to Vascular Interventions 19 September 2017 - HELSINKI AND STOCKHOLM, September 19, 2017. Aplagon Oy (“Aplagon”) and Cadila Pharmaceuticals Sweden AB today announced a development and commercialization agreement for Aplagon’s lead APAC product. APACs are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury. Under the agreement, Cadila Pharmaceuticals Sweden AB together with its… read more »
Events
Aplagon will be represented at the following partnering or scientific meetings.
- BIO-Europe 2022
- ISTH 2022
ISTH 2022
July 9-13, London
Read more